13:21 · 25 June 2024

Novo Nordisk climbs 2.2% to all-time high amid Wegovy green light in China 📈

Shares of famous Danish weight-drug loss producer Novo Nordisk (NOVOB.DK) are reaching now all-time highs above 1000 DKK as Wegovy weight-loss treatment received approval from regulators in China.

  • Novo Nordisk didn't comment when exactly it will be selling its products on Chinese market. Supply nor Wegovy prices on Chinese market are not known. According to a Chinese public health study, number of overweight adults in China can reach 540 million by 2030 rising 280% since 2000 level.
  • Novo Nordisk is currently the highest valued, European company and year-to-date Novo risen almost 45%. Yesterday, on Monday 24 June, the company announced $4.1 facility investment in the North Carolina (US), to boost its manufacturing capabilities.

Novo Nordisk (NOVOB.DK, D1 interval)

During last 12 months the most important support zone for Novo Nordisk was near SMA50 (orange line) and in correction scenario levels near 900-920DKK may be important.Source: xStation5

1 October 2026, 09:24

Risk aversion to start the month

30 September 2026, 21:46

Record after record: Micron smashes Q4 results, server overload crashes website, stock surges post-market

30 September 2026, 18:42

📊Daily Summary: PCE inflation slowdown brings relief to Wall Street, but oil continues gains despite return of supply

30 September 2026, 15:01

US OPEN: Lower Core PCE inflation gives relief to Wall Street, markets rise after GDP revision

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.